Cargando…

Comparison of Immunotherapy, Chemotherapy, and Chemoimmunotherapy in Advanced Pulmonary Lymphoepithelioma-Like Carcinoma: A Retrospective Study

Pulmonary lymphoepithelioma-like carcinoma (pLELC) is a rare subtype of lung cancer that is associated with the Epstein-Barr virus in Asia. Due to the lack of prospective studies, the best first-line treatment and survival outcomes remain unclear. Herein, This study investigated the efficacy and saf...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Yi, He, Jinyuan, Luo, Shaoning, Dong, Min, Li, Wei, Liu, Gaijiao, Chen, Hongjie, Yang, Xiongwen, Huang, Shaohong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8882604/
https://www.ncbi.nlm.nih.gov/pubmed/35237520
http://dx.doi.org/10.3389/fonc.2022.820302
_version_ 1784659730426232832
author Xiao, Yi
He, Jinyuan
Luo, Shaoning
Dong, Min
Li, Wei
Liu, Gaijiao
Chen, Hongjie
Yang, Xiongwen
Huang, Shaohong
author_facet Xiao, Yi
He, Jinyuan
Luo, Shaoning
Dong, Min
Li, Wei
Liu, Gaijiao
Chen, Hongjie
Yang, Xiongwen
Huang, Shaohong
author_sort Xiao, Yi
collection PubMed
description Pulmonary lymphoepithelioma-like carcinoma (pLELC) is a rare subtype of lung cancer that is associated with the Epstein-Barr virus in Asia. Due to the lack of prospective studies, the best first-line treatment and survival outcomes remain unclear. Herein, This study investigated the efficacy and safety of different treatment regimens for advanced pLELC. This retrospective study included 68 patients with advanced pLELC from two centers in China. Patients were divided into three groups according to different first-line treatments: chemotherapy (n=49, 72.1%), immunotherapy (n=7, 10.3%), and chemoimmunotherapy (n=12,17.6%). The primary endpoint of this study was the 2-year progression-free survival (PFS) of each group. The results show that the median PFS was 6.9 months (range, 2.3–not estimable) in the chemotherapy group, 11.0 months (range, 2–not estimable) in the immunotherapy group, and 11.8 months (range, 6–not estimable) in the chemoimmunotherapy group. There was a significant difference in 2-year PFS between the chemoimmunotherapy group and the chemotherapy group (hazard ratio, 0.38, 95% confidence interval: 0.18-0.78, log-rank P=0.007). The most frequent grade 3-4 adverse event in the chemotherapy and chemoimmunotherapy groups was myelosuppression (10/49 [22.4%] and 4/12 [33.3%], respectively). The most frequent grade 3-4 adverse events in the immunotherapy group were diarrhea (1/7, 14.8%) and hepatotoxicity (1/7, 14.8%). Chemoimmunotherapy had the highest 2-year PFS as a first-line treatment for advanced pLELC compared to chemotherapy and immunotherapy. This study suggests that chemoimmunotherapy may be the best first-line treatment for patients with advanced pLELC.
format Online
Article
Text
id pubmed-8882604
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88826042022-03-01 Comparison of Immunotherapy, Chemotherapy, and Chemoimmunotherapy in Advanced Pulmonary Lymphoepithelioma-Like Carcinoma: A Retrospective Study Xiao, Yi He, Jinyuan Luo, Shaoning Dong, Min Li, Wei Liu, Gaijiao Chen, Hongjie Yang, Xiongwen Huang, Shaohong Front Oncol Oncology Pulmonary lymphoepithelioma-like carcinoma (pLELC) is a rare subtype of lung cancer that is associated with the Epstein-Barr virus in Asia. Due to the lack of prospective studies, the best first-line treatment and survival outcomes remain unclear. Herein, This study investigated the efficacy and safety of different treatment regimens for advanced pLELC. This retrospective study included 68 patients with advanced pLELC from two centers in China. Patients were divided into three groups according to different first-line treatments: chemotherapy (n=49, 72.1%), immunotherapy (n=7, 10.3%), and chemoimmunotherapy (n=12,17.6%). The primary endpoint of this study was the 2-year progression-free survival (PFS) of each group. The results show that the median PFS was 6.9 months (range, 2.3–not estimable) in the chemotherapy group, 11.0 months (range, 2–not estimable) in the immunotherapy group, and 11.8 months (range, 6–not estimable) in the chemoimmunotherapy group. There was a significant difference in 2-year PFS between the chemoimmunotherapy group and the chemotherapy group (hazard ratio, 0.38, 95% confidence interval: 0.18-0.78, log-rank P=0.007). The most frequent grade 3-4 adverse event in the chemotherapy and chemoimmunotherapy groups was myelosuppression (10/49 [22.4%] and 4/12 [33.3%], respectively). The most frequent grade 3-4 adverse events in the immunotherapy group were diarrhea (1/7, 14.8%) and hepatotoxicity (1/7, 14.8%). Chemoimmunotherapy had the highest 2-year PFS as a first-line treatment for advanced pLELC compared to chemotherapy and immunotherapy. This study suggests that chemoimmunotherapy may be the best first-line treatment for patients with advanced pLELC. Frontiers Media S.A. 2022-02-14 /pmc/articles/PMC8882604/ /pubmed/35237520 http://dx.doi.org/10.3389/fonc.2022.820302 Text en Copyright © 2022 Xiao, He, Luo, Dong, Li, Liu, Chen, Yang and Huang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Xiao, Yi
He, Jinyuan
Luo, Shaoning
Dong, Min
Li, Wei
Liu, Gaijiao
Chen, Hongjie
Yang, Xiongwen
Huang, Shaohong
Comparison of Immunotherapy, Chemotherapy, and Chemoimmunotherapy in Advanced Pulmonary Lymphoepithelioma-Like Carcinoma: A Retrospective Study
title Comparison of Immunotherapy, Chemotherapy, and Chemoimmunotherapy in Advanced Pulmonary Lymphoepithelioma-Like Carcinoma: A Retrospective Study
title_full Comparison of Immunotherapy, Chemotherapy, and Chemoimmunotherapy in Advanced Pulmonary Lymphoepithelioma-Like Carcinoma: A Retrospective Study
title_fullStr Comparison of Immunotherapy, Chemotherapy, and Chemoimmunotherapy in Advanced Pulmonary Lymphoepithelioma-Like Carcinoma: A Retrospective Study
title_full_unstemmed Comparison of Immunotherapy, Chemotherapy, and Chemoimmunotherapy in Advanced Pulmonary Lymphoepithelioma-Like Carcinoma: A Retrospective Study
title_short Comparison of Immunotherapy, Chemotherapy, and Chemoimmunotherapy in Advanced Pulmonary Lymphoepithelioma-Like Carcinoma: A Retrospective Study
title_sort comparison of immunotherapy, chemotherapy, and chemoimmunotherapy in advanced pulmonary lymphoepithelioma-like carcinoma: a retrospective study
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8882604/
https://www.ncbi.nlm.nih.gov/pubmed/35237520
http://dx.doi.org/10.3389/fonc.2022.820302
work_keys_str_mv AT xiaoyi comparisonofimmunotherapychemotherapyandchemoimmunotherapyinadvancedpulmonarylymphoepitheliomalikecarcinomaaretrospectivestudy
AT hejinyuan comparisonofimmunotherapychemotherapyandchemoimmunotherapyinadvancedpulmonarylymphoepitheliomalikecarcinomaaretrospectivestudy
AT luoshaoning comparisonofimmunotherapychemotherapyandchemoimmunotherapyinadvancedpulmonarylymphoepitheliomalikecarcinomaaretrospectivestudy
AT dongmin comparisonofimmunotherapychemotherapyandchemoimmunotherapyinadvancedpulmonarylymphoepitheliomalikecarcinomaaretrospectivestudy
AT liwei comparisonofimmunotherapychemotherapyandchemoimmunotherapyinadvancedpulmonarylymphoepitheliomalikecarcinomaaretrospectivestudy
AT liugaijiao comparisonofimmunotherapychemotherapyandchemoimmunotherapyinadvancedpulmonarylymphoepitheliomalikecarcinomaaretrospectivestudy
AT chenhongjie comparisonofimmunotherapychemotherapyandchemoimmunotherapyinadvancedpulmonarylymphoepitheliomalikecarcinomaaretrospectivestudy
AT yangxiongwen comparisonofimmunotherapychemotherapyandchemoimmunotherapyinadvancedpulmonarylymphoepitheliomalikecarcinomaaretrospectivestudy
AT huangshaohong comparisonofimmunotherapychemotherapyandchemoimmunotherapyinadvancedpulmonarylymphoepitheliomalikecarcinomaaretrospectivestudy